The National Medical Products Administration (NMPA) has approved the first CAR T-cell therapy called Yescarta for China, which has been found to be successful in treating certain kinds of late-stage blood cancer. Fosun Pharma Kite Biotechnology will market Yescarta in China, a treatment meant for adults diagnosed with B-cell lymphoma that have not responded to 2 other treatments or have relapsed. Terence O’Sullivan, VP, International Region at Kite, stated, “In relapse or refractory LBCL, current standard-of-care is associated with poor long-term outcomes, so we are pleased to offer this new hope of survival for patients in China who are in need to new therapeutic options.”

Read more here.

More on: